

## CURRICULUM VITAE

Prof. Dr. med. Stephan Stilgenbauer

Date of birth: November 27, 1966

Nationality: German

Marital status: Married to Dr. med. Franziska Stilgenbauer, two sons

Position: Professor of Medicine and Director

Klinik für Innere Medizin I, Saarland University Medical Center

Gebäude 41.1, Kirrberger Str. 100, D-66421 Homburg, Germany

Tel +49 – (0) 68 41 – 16 – 15010; Fax +49 – (0) 68 41 – 16 – 15012

E-Mail: stephan.stilgenbauer@uks.eu

### University education

- 1987 - 1994 University of Heidelberg Medical School, Germany. Electives in Hamilton, Canada; Jerusalem, Israel; Bath, UK and Cambridge, UK
- 1993 Final year medical school ("Praktisches Jahr") at Baylor College of Medicine and M.D. Anderson Cancer Center, Houston, Texas, USA
- 1994 MD degree ("Staatsexamen")
- 1994 Doctoral thesis degree ("Dr. med."), magna cum laude, Ruprecht-Karls-Universität Heidelberg, Doktorvater Prof. Dr. P. P. Nawroth

### Postgraduate training

- 1994 - 1999 Residency in internal medicine and fellowship in hematology-oncology at the Medizinische Klinik und Poliklinik V, University of Heidelberg, Germany (Directors: Prof. Dr. med. W. Hunstein -1996, Prof. Dr. med. R. Haas 1996-1998, Prof. Dr. med. Anthony D. Ho since 1998)
- 1996 - 1998 Postdoctoral laboratory research fellow at the Department "Organization of complex genomes" of the Deutsche Krebsforschungszentrum, Heidelberg, Germany (Head: Prof. Dr. rer. nat. Peter Lichter)
- Since 1999 Department of Internal Medicine III, Ulm University, Germany (Director: Prof. Dr. med. Hartmut Döhner)
- 2002 Boards in Internal Medicine
- 2002 Venia legendi in Internal Medicine
- Since 2003 Attending physician ("Oberarzt")
- 2004 Boards in Hematology and Medical Oncology
- 2005 Professorship at Ulm University ("Außerplanmäßige Professur")
- 2008-2018 Deputy Chairman, Department of Internal Medicine III (Hematology, Oncology, Rheumatology and Infectious Diseases), Ulm University, Ulm, Germany
- Since 2018 Professor and Chairman, Department of Internal Medicine I (Hematology, Oncology, Clinical Immunology, Rheumatology), Saarland University, Homburg, Germany

### Positions and memberships in organizations and panels (selection)

- Member of the Ethics Committee Ulm University
- Member, Competence Network "Maligne Lymphome"
- Core Group Member, International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
- Author of the CLL chapter of "UpToDate®"
- Scientific Program Committee, European Hematology Association (EHA) 2015
- Module Director, Online Master Program "Advanced Oncology", Ulm University
- Chairman, Certificate of Competence in Lymphoma, European School of Oncology
- Subsection Editor of Section 2 "Malignant Lymphoid Diseases", "The EHA Research Roadmap for Blood Disorders in Europe", 2015

- Scientific Chair, ESH Conference NEW CONCEPTS IN B CELL MALIGNANCIES: from molecular pathogenesis to personalized treatment, Estoril, 2016
- Member of the steering committees, Deutschen CLL Studiengruppe (DCLLSG) and Deutsche Studiengruppe Hochmaligne Lymphome (DSHNHL)
- Data Safety Monitoring Board of clinical trials (HOVON, Roche, GSK, etc.)
- Speaker/Chair, Educational Program, Annual Meetings of the European Hematology Association (2014, 2012, etc.) European Bone Marrow Transplantation (2014), American Society of Hematology (2004, 2010, 2015) American Society of Clinical Oncology (2015)

### Reviewer positions (selection)

- Journals: N Engl J Med, Lancet, Nat Med, Nat Genet, J Clin Invest, J Exp Med, Blood, J Clin Oncol, Ann Oncol, Leukemia, Oncogene, Brit J Haematol, Int J Cancer, Biotechniques, Genes Chromosomes Cancer, Haematologica, Leuk Lymphoma, etc.
- Agencies and organizations: DFG, Deutsche Krebshilfe, Wilhelm Sander Stiftung, Leukemia Research Fund (LRF) UK, Medical Research Council (MRC) UK, Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), HOVON-Studiengruppe, Italian Association for Cancer Research (AIRC), European Hematology Association (EHA), CLL Global Research Foundation (CLLGRF), Lymphoma Research Foundation (LRF), American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), etc.

### Research grant funding (summary)

European Commission, BMBF, DFG, Helmholtz Gemeinschaft, Deutsche Krebshilfe, Deutsche José Carreras Leukämie-Stiftung, Else Kröner-Fresenius Stiftung, Wilhelm Sander Stiftung, Land Baden-Württemberg, CLL Global Research Foundation, industry funding, etc.

### Awards and honors

- DAAD scholarship, final year medical school, Houston, Texas, 1993
- Best Abstract Award, Deutsche Gesellschaft für Hämatologie und Onkologie, 2000
- Franziska Kolb Award, Ulm University, 2001
- Artur Pappenheim Award, Deutsche Gesellschaft für Hämatologie und Onkologie, 2002
- Merckle Award, Ulm University, 2006
- Walther und Christine Richtzenhain Award, Deutsches Krebsforschungszentrum, 2008
- Paul Martini Award, Deutsche Gesellschaft für Innere Medizin, 2012

### Most important publications

1. Stilgenbauer S\*, Schaffner C\*, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Döhner H: Biallelic mutations in the *ATM* gene in T-prolymphocytic leukemia. **Nature Med** 3(10):1155-1159, 1997 \*Equal contribution
2. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. **Lancet** 376(9747):1164-1174, 2010
3. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S: From pathogenesis to treatment of chronic lymphocytic leukaemia. **Nature Rev Cancer** 10(1):37-50, 2010
4. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer

S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC: Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. **N Engl J Med** 370(24):2286-94, 2014

5. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. **Blood** 123(21):3247-54, 2014
6. Landau DA\*, Tausch E\* Taylor-Weiner AN\*, Stewart, C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Cibulskis K, Mertens D, Sougnez C, Rosenberg M, Hess JM, Carter SL, Edelmann J, Kless S, Fink A, Fischer K, Gabriel S, Lander E, Nowak MA, Döhner H, Hallek M\*, Neuberg D\*, Getz G\*, Stilgenbauer S\*, Wu CJ\*. Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse. **Nature** 526(7574):525-30, 2015 \*Equal contribution
7. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowicz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. **Nature Genet** 48(3):253-64, 2016
8. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: a Phase 2, Open Label, Multicenter Study. **Lancet Oncology** 17(6): 768-78, 2016
9. Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. **J Clin Oncol**; 36(19):1973-1980, 2018.
10. Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. IGF1R as druggable target mediating PI3K- $\delta$  inhibitor resistance in a murine model of chronic lymphocytic leukemia. **Blood** Prepub online Apr 22, 2019.
11. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. **N Engl J Med**. 380(23):2225-2236, 2019.